Cold Agglutinin Disease 2020 Market Spotlight - Licensing and Asset Acquisition Deals - ResearchAndMarkets.com
Retrieved on:
Friday, July 3, 2020
This Market Spotlight report covers the Cold Agglutinin Disease market, comprising disease background and treatment information, key pipeline drugs, clinical trials, probability of success, licensing and acquisition deals, and an epidemiology overview.
Key Points:
- This Market Spotlight report covers the Cold Agglutinin Disease market, comprising disease background and treatment information, key pipeline drugs, clinical trials, probability of success, licensing and acquisition deals, and an epidemiology overview.
- There are only two industry-sponsored drugs in active clinical development for cold agglutinin disease, with one drug each in Phase II and Phase III
Therapies in development for cold agglutinin disease target the complement pathway. - There have been only two licensing and asset acquisition deals involving cold agglutinin disease drugs during 2015-20.
- Sanofi leads industry sponsors with the highest number of clinical trials for cold agglutinin disease.